India, Sept. 15 -- Several biotech stocks were in focus Tuesday, including PDS Biotech following a potential $22.55 million PIPE financing; Avai Bio after completing testing of its GMP Master Cell Bank; Clene following a $4 million registered direct offering; NurExone after entering an MOU with NanoPass; Cardiff Oncology following a licensing dispute settlement; and Indaptus Therapeutics despite no specific company news behind its move.
Read on.
PDS Biotech (PDSB) shares are gaining attention after the company announced an equity financing of up to $22.55 million in a PIPE transaction led by Nant Capital, LLC and Dr. Patrick Soon-Shiong. The financing includes an initial closing expected to raise approximately $11.55 million, with an addi...